Comparative Pharmacology
Head-to-head clinical analysis: IFOSFAMIDE versus VIVIMUSTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IFOSFAMIDE versus VIVIMUSTA.
IFOSFAMIDE vs VIVIMUSTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prodrug activated by cytochrome P450 to cytotoxic metabolites (4-hydroxyifosfamide, acrolein, and ifosforamide mustard) that alkylate DNA by cross-linking guanine bases, inhibiting DNA replication and transcription.
VIVIMUSTA is a nitrogen mustard alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, leading to cell death.
1.2 g/m² IV over 2 hours daily for 5 consecutive days every 3 weeks, or 5 g/m² IV as a 24-hour continuous infusion every 3 weeks. Administer with mesna and vigorous hydration.
100 mg/m2 intravenously over 30 minutes on days 1-3 of a 21-day cycle.
None Documented
None Documented
Terminal half-life: 4-7 hours for parent drug; active metabolite 4-desulfonate has half-life ~12-15 hours. Clinical context: Prolonged with renal impairment.
Clinical Note
moderateIfosfamide + Digoxin
"Ifosfamide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateIfosfamide + Digitoxin
"Ifosfamide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateIfosfamide + Deslanoside
"Ifosfamide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateIfosfamide + Acetyldigitoxin
"Ifosfamide may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is 12 hours (range 10-14 h) in adults with normal renal function; prolonged to 24-36 h in moderate renal impairment (CrCl 30-50 mL/min).
Primarily renal: 50-60% excreted unchanged in urine. Biliary/fecal excretion is minimal (<5%).
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Category D/X
Category C
Alkylating Agent
Alkylating Agent